Related Experiment Video

Updated: Aug 21, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Molecular remission with arsenic trioxide in patients with newly diagnosed acute promyelocytic leukemia

Biju George, Likram Mathews, Poonkuzhali Balasubramanian

    Haematologica
    |October 13, 2004
    PubMed

    Insights

    Arsenic trioxide (As2O3) effectively induces remission in acute promyelocytic leukemia (APML) patients. Most patients achieve molecular remission during consolidation therapy, with sustained remission rates at 20 months, though long-term monitoring is crucial.

    Area of Science:

    • Hematology
    • Oncology
    • Molecular Biology

    Background:

    • Acute promyelocytic leukemia (APML) is a distinct subtype of acute myeloid leukemia.
    • Arsenic trioxide (As2O3) has emerged as a highly effective therapeutic agent for APML.
    • Achieving and maintaining molecular remission is critical for long-term patient outcomes.

    Purpose of the Study:

    • To evaluate the molecular remission rates in APML patients treated with As2O3.
    • To assess the durability of remission in APML patients undergoing As2O3 therapy.
    • To determine the need for extended follow-up in APML patients treated with As2O3.

    Main Methods:

    • Serial monitoring of 36 APML patients using Reverse Transcription Polymerase Chain Reaction (RT-PCR).
    • Patients achieved hematological remission prior to monitoring.
    • Follow-up duration extended to 20 months.

    Main Results:

    • Only 5.5% of patients achieved molecular remission at the induction remission phase.
    • A significant increase to 94.5% achieved molecular negativity during the consolidation phase.
    • At 20 months follow-up, 85% of patients remained in remission.

    Conclusions:

    • Consolidation therapy with As2O3 significantly enhances molecular remission rates in APML.
    • Sustained remission is observed in a high percentage of patients at 20 months.
    • Longer follow-up studies are necessary to monitor for potential late relapses in APML patients treated with As2O3.

    Related Concept Videos